Rapport Therapeutics, Inc. RAPP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$107.28M+3.8% | -$111.48M-14.1% | -$97.7M-10.6% | -$88.31M-10.8% | -$79.7M-1.8% | ||
| $1M-1.7% | $1.02M+0.5% | $1.01M+3.8% | $975K+4.7% | $931K+11.0% | ||
| $21.78M+15.5% | $18.86M+15.2% | $16.37M+10.5% | $14.82M+15.9% | $12.78M+24.9% | ||
| -$80.3M+8.2% | -$87.47M-13.3% | -$77.22M-1.4% | -$76.17M-12.9% | -$67.45M-4.0% | ||
| $411K-33.3% | $616K-8.5% | $673K-0.9% | $679K-58.2% | $1.62M-32.5% | ||
| -$170.56M+9.0% | -$187.47M— | —— | —— | —— | ||
| $271.31M+0.2% | $270.79M+0.1% | $270.48M+530,457% | -$51K-100% | $159.37M-28.5% | ||
| $20.45M+592% | -$4.16M— | —— | —— | —— | ||
| -$80.71M+8.4% | -$88.09M-13.1% | -$77.89M-1.4% | -$76.85M-11.3% | -$69.07M-2.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Rapport Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.